Immunoglobulin E (IgE) plays a key role in the pathogenesis of many allergic diseases. Thus, IgE-mediated immunologic pathways are an attractive target for intervention in allergic diseases. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthm...

We report 2 patients with cold urticaria with different response to treatment with omalizumab (Xolair(®)). Cold contact urticaria (CCU) is a common subtype of physical urticaria. It is characterized by the development of wheal and/or angioedema within minutes after cold contact. Clinical manifestation of CCU can range from mild, localized whealing to life-threatening anaphylactic shock reaction...

RESULTS. Compared with placebo, omalizumab treatment significantly reduced the mean number of symptomatic days per 2-week interval from 1.96 to 1.48, which is a 24.5% difference (P .001). Significantly fewer exacerbations occurred during the treatment period in the omalizumab group; 30.3% of patients had an exacerbation compared with 48.8% of patients in the placebo group (P .001). Similarly, t...

RESULTS. Compared with placebo, omalizumab treatment significantly reduced the mean number of symptomatic days per 2-week interval from 1.96 to 1.48, which is a 24.5% difference (P .001). Significantly fewer exacerbations occurred during the treatment period in the omalizumab group; 30.3% of patients had an exacerbation compared with 48.8% of patients in the placebo group (P .001). Similarly, t...

Omalizumab, a humanized monoclonal anti-IgE antibody has the potential to alter allergen processing. Recently, it has been postulated the assessment of PHA-stimulated adenosine triphosphate (ATP) activity as maker of CD4+ T cells activity in peripheral blood cells. We present the case report of a 35-year-old woman with a history of chronic idiopathic urticaria and angioedema of 8 years of devel...

BACKGROUND Some asthma patients remain poorly controlled despite receiving care consistent with treatment guidelines. OBJECTIVE This study compared the ability to sleep, work, and participate in leisure activities among subjects with immunoglobulin E-mediated (allergic) asthma initiating omalizumab (omalizumab start group) with subjects receiving moderate-to-high doses of salmeterol/fluticaso...

Background Evidence for systemic treatments severe childhood eczema is limited. Systemic immunosuppressants are unlicensed use in children and associated with unwanted side effects. Objective To examine the role of anti-immunoglobulin E (IgE) [omalizumab (Xolair ® , Novartis Pharmaceuticals UK Ltd, Frimley, UK)] young people eczema. Design A double-blind, placebo-controlled, parallel-arm random...

A 62-year-old male patient with type 2 diabetes for 16 years developed a severe anaphylactic shock upon administration of intravenous, short-acting regular insulin. The patient's medical history comprised allergic reactions to an unknown agent as a child as well as injection site reactions, urticaria, and dyspnea to subcutaneous NPH-insulin injections. The diagnostic work-up revealed a type 1 I...

Omalizumab is a recombinant humanized monoclonal antibody that reduces levels of circulating IgE and expression of IgE high affinity receptor (FCɛRI) on mast cells and basophils. Its role in the therapy of allergic asthma and urticaria is well established. According to GINA guidelines, omalizumab should be considered as an important alternative to systemic corticosteroids in uncontrolled asthma...

Background Patients with severe allergic asthma (SAA) are often inadequately controlled despite available treatments including high-dose inhaled corticosteroids and longacting b2-agonists. Use of oral corticosteroids (OCS) in SAA patients may not achieve full asthma control, and leads to significant long-term side effects. Omalizumab is a recombinant humanized monoclonal anti-immunoglobulin E (...